to-BBB technologies BV
about toBBB technology products partnering news contact
 
 
 

to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier.

to-BBB’s vision is that the treatment of currently unserved brain diseases will be best achieved by safely enhancing the blood-to-brain delivery of drugs.

The company is developing novel treatments for devastating brain disorders by combining existing drugs with its proprietary brain delivery platform. 

 

 

 

LATEST NEWS:

FDA grants Orphan Drug Status for to-BBB’s lead product, August 23

to-BBB featured in the Neurotech Insights issue focus on blood-brain barrier, August 01

to-BBB receives positive opinion for Orphan Drug Designation, June 14

to-BBB announces brain drug delivery pilot study with Janssen Pharmaceutica NV for CNS diseases, May 20

to-BBB and GSK to collaborate on brain delivery of a biologic product, March 03

 

PIPELINE:

FACT SHEETS:

Please see the corporate factsheet and the G-Technology factsheet for an overview of   to-BBB and its core technology platform.

 

LATEST PRESS RELEASE:

Download here our latest press release.

 

MEDIA COVERAGE:

To find the latest coverage of to-BBB in the media, please click here.

 

 

 

(photo: Aad van Vliet / TwoMoves)

copyright 2007 - toBBB - disclaimer